| 0 (0%) | 11-04 16:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.42 |
1-year : | 4.7 |
| Resists | First : | 2.92 |
Second : | 4.03 |
| Pivot price | 1.67  |
|||
| Supports | First : | 1.14 |
Second : | 0.95 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 1.58 |
| MA(100) : | 1.12 |
MA(250) : | 1.01 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 63.6 |
D(3) : | 73.9 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 4.03 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRLD ] has closed above bottom band by 47.8%. Bollinger Bands are 512.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.04 - 4.05 | 4.05 - 4.07 |
| Low: | 1.42 - 1.42 | 1.42 - 1.43 |
| Close: | 3.95 - 3.98 | 3.98 - 4.01 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Tue, 04 Nov 2025
Major Shift in PRLD Stock: What’s Behind the Surge? - StocksToTrade
Tue, 04 Nov 2025
Prelude Therapeutics’ Stock Performance: Rise or Risk? - timothysykes.com
Tue, 04 Nov 2025
Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today? - TipRanks
Tue, 04 Nov 2025
Prelude Therapeutics pauses clinical development of SMARCA2 degrader program (PRLD:NASDAQ) - Seeking Alpha
Tue, 04 Nov 2025
Prelude Therapeutics Announces Management Changes - TradingView
Tue, 04 Nov 2025
PRLD's Financial Outlook: Cash Runway Extended to 2027 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.917e+007 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 538 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3325e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 928.6 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 7e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -75.86 |
| EBITDA (p.s.) | 5.51181e+006 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 2.05 |
| Dividend | 0 |
| Forward Dividend | 515090 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|